The Zacks Analyst Blog Highlights Hinge Health, OPKO Health, Globus Medical and Merit Medical Systems

Hinge Health (HNGE) stock surged 146.3% YTD, outperforming the industry and S&P 500. Q3 revenue grew 52% YoY to $235M, with operating margin expanding to 33%. The company raised 2026 revenue guidance to $879-$881M. Growth is driven by member engagement, AI efficiencies, and expansion into migraine and GI care. Risks include execution challenges in new care categories. Zacks ranks HNGE as Strong Buy.

Original reporting
Published Nov 19, 2026, 9:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 11:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Zacks Analyst Blog Highlights Hinge Health, OPKO Health, Globus Medical and Merit Medical Systems — source image
Decision brief

The 30-second read

$HNGEBullishMed
01

Why it matters

Guidance raise is a primary disclosure that can move the stock.

02

Market read

New guidance for Hinge Health may attract growth‑oriented investors.

03

What to watch

Execution risk of new GI and migraine programs could delay revenue impact.

Relevance 7/10Novelty 8/10Timing: today

Background

Zacks Analyst Blog highlights recent performance and guidance updates for Hinge Health and other medical stocks.

Company-level read

Ticker impact

$HNGEBullishHigh confidence
Context

Zacks blog reports Hinge Health raised 2026 revenue guidance to $879‑$881 million, a fresh upward revision.

Expected impact

upward pressure as investors price in higher revenue outlook

Evidence & confidence

Revenue guidance increase of ~50% at the midpoint is material and likely to boost the stock.

Market effects

Highlights growth potential in digital health sector.

U.S. digital health stocks may see increased interest.

Limited to health‑tech investors.

Counterpoint

Guidance may be overly optimistic if member engagement stalls.

Key entities

  • Hinge Health

    Digital health provider with new revenue guidance.

Related articles

$OPKHighAI 8/10

OPKO Slips To Loss In Q3 On Impact Of Discontinued Operations, Revenue Up

OPKO Health reported a Q3 net loss of $53.5M, or $0.07 per share, compared to a profit of $21.6M a year earlier. Revenue from continuing operations rose 16% to $65.4M. The company agreed to sell remaining BioReference operations to Labcorp for up to $872M. OPKO also issued $125M in senior secured royalty notes and provided updates on several clinical trials. Full-year 2026 revenue is expected between $268M and $278M.

$GMEDHighAI 8/10

Why Globus Medical (GMED) shares are plunging today

Globus Medical (GMED) shares fell 11.6% after reporting Q3 2026 revenue of $763.7M, below estimates, and lowering full-year revenue guidance to $3.09B. Adjusted EPS of $1.23 beat estimates. The company cited product launch delays and revenue recovery issues. The board authorized a $500M share repurchase program.

$GMEDHighAI 8/10

Globus Medical Inc (GMED) Q3 2026 Earnings Call Highlights: Revenue Miss, Nevro Weakness

Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, missing expectations and lowering full-year guidance to $3.09B. Nevro revenue declined 25.7% YoY, and US Spine growth slowed. Despite this, free cash flow reached a record $225M, and gross margins expanded to 69.5%. The company expects 2027 growth from new products and market expansion, with mid- to high-single-digit revenue growth targeted.

$GMEDMedAI 8/10

Globus Medical Q3 Earnings Call Highlights

Globus Medical (GMED) reported Q3 earnings with GAAP net income of $141.2M and adjusted net income of $167M. The company expects a mid-single-digit revenue decline in Q4 due to delayed product launches and slower recovery at Nevro. Nevro's revenue fell 9% sequentially, but adjusted EBITDA margin improved to 19.9%. Globus plans to launch a new implantable pulse generator in 2027 and completed two small acquisitions. Operating cash flow rose 6% to $265M, and free cash flow increased 5% to $225M.